Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00410904 · ClinicalTrials.gov registry record · Phase 2

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

A Phase 2 study of Recurrent Non-small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
2
Study locations

NCT00410904 is a Phase 2 study of Recurrent Non-small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants, below the 143-participant average among 15 other Recurrent Non-small Cell Lung Cancer trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00410904, a Phase 2 study of Recurrent Non-small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial is studying how well giving AZD2171 together with pemetrexed disodium works in treating patients with relapsed non-small cell lung cancer. AZD2171 and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. AZD2171 may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving AZD2171 together with pemetrexed disodium may kill more tumor cells.

Conditions Studied

Recurrent Non-small Cell Lung Cancer

Interventions

  • DRUG pemetrexed disodium
  • DRUG cediranib maleate

Study Locations (2)

Maryland

  • University of Maryland/Greenebaum Cancer Center - Baltimore

Michigan

  • Wayne State University/Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2006-10
Est. Completion 2014-03
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00410904

The ClinicalTrials.gov registry entry for NCT00410904 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 15 other Recurrent Non-small Cell Lung Cancer trials with a reported enrollment target (58% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Recurrent Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which pemetrexed disodium is the first listed.

NCT00410904 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Michigan.

Frequently Asked Questions

What is clinical trial NCT00410904 about?

NCT00410904 is a clinical study titled "AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer". This phase II trial is studying how well giving AZD2171 together with pemetrexed disodium works in treating patients with relapsed non-small cell lung cancer. AZD2171 and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. AZD2171 may also s...

What is the current status of trial NCT00410904?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-10. Estimated completion is 2014-03.

What conditions does trial NCT00410904 study?

This clinical trial studies the following conditions: Recurrent Non-small Cell Lung Cancer.

What interventions are being tested in trial NCT00410904?

The interventions under investigation include: pemetrexed disodium (DRUG), cediranib maleate (DRUG).

Who is sponsoring clinical trial NCT00410904?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00410904 being conducted?

This trial has 2 study locations across Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Non-small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Non-small Cell Lung Cancer

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.